Top Markets
#1 Purr Purr +63.76%
#2 Pons Pons +51.76%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 Non-Playable Coin Non-Playable Coin +34.60%
#5 ApeX ApeX +29.89%
#6 Kinetiq Kinetiq +27.29%
#7 Morpho Morpho +24.45%
#8 StonkBroker StonkBroker +23.94%
#9 Cash Cat Cash Cat +23.07%
#10 OriginTrail OriginTrail +21.94%
Coin of the day
Purr Purr
Settings
Language
ENGLISH
Currency
USD
Theme
SynAct Pharma AB SynAct Pharma AB

SynAct Pharma AB

SYNACT
Rank in Stocks #20988
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS,... SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Share Price
$2.22
Last synced: 2026-08-21
Market Cap
$117.70M
Change (1 day)
2.69%
Change (1 year)
17.26%
Country
SE
Trade SynAct Pharma AB (SYNACT)

Category

Healthcare
P/E ratio for SynAct Pharma AB (SYNACT)
P/E ratio as of 2026 TTM: 0
According to SynAct Pharma AB latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for SynAct Pharma AB from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.